The purpose of this study is to evaluate the safety and preliminary effectiveness of an investigational drug called AMP-224 when given with the conventional chemotherapy agent cyclophosphamide in patients with advanced melanoma that is no longer responding to standard treatments.
AMP-224 boosts the body’s immune system by targeting a protein on white blood cells called PD-1. PD-1 normally maintains the balance of the immune system by shutting it down at the right time. Some cancers take advantage of this shut-down mechanism by activating PD-1, enabling them to escape attack by the body’s white blood cells.
AMP-224 binds to and inactivates PD-1, enhancing the body’s ability to detect and destroy cancer cells. It is hoped that by combining it with chemotherapy drugs, such as cyclophosphamide, cancer cell death can be enhanced.